Analyst Cuts Hit Amdocs Ahead of Next Week's Results

Amdocs heads into its November 11 earnings report with fresh analyst pressure landing on the same day as a stock already carrying meaningful short interest.

The analyst moves this week tell the most urgent story. Stifel's Shlomo Rosenbaum cut his price target from $71 to $46 on November 4, a 35% reduction, while keeping a Buy rating. That's a striking gap: maintaining conviction on direction while slashing the target by that magnitude suggests a significant revision to near-term earnings expectations. Oppenheimer simultaneously downgraded the stock from Outperform to Perform. These two actions, arriving together the day before the data snapshot closed, sharpen the bearish framing heading into the print. The mean analyst target across the broader coverage universe stands at $73, well above the current price of $62.43, but Stifel's $46 target now sits 26% below where the stock is trading, which is a notable divergence from the consensus direction. The bear case is straightforward: AT&T and T-Mobile together account for roughly 47% of revenue, management's guidance for fiscal Q3 adjusted EPS of $1.81 to $1.87 came in below the $1.90 estimate, and the phase-out of low-margin businesses created about $600 million in fiscal 2025 revenue headwinds. Stifel's target cut suggests at least one major bull is recalibrating how quickly those pressures resolve.

Short interest at 7.5% of the free float is meaningful but not extreme, and the positioning picture is more nuanced than the analyst headlines imply. Shorts actually trimmed positions over the past month, with shares short falling roughly 7% from late September levels, when the position peaked near 9.2 million shares. The step-down came abruptly around October 23, when short interest fell from 8.8 million to 8.3 million shares in a single session and has held near that level since. Borrowing costs are low, running at 0.41% with a 31% week-on-week decline, and the lending market is loose. Availability is at 850% of outstanding short interest, meaning there are more than eight shares available to borrow for every one already borrowed. That's well above the 52-week trough of 322%, which occurred on September 30 when utilization briefly spiked to 24%. The current setup does not look like a building short squeeze or a deteriorating borrow market. If anything, the retreat in short positions over the past five weeks suggests some bears covered ahead of earnings rather than adding.

Options positioning reinforces the cautious but not panicked tone. The put/call ratio of 4.61 looks alarming in isolation, but it sits almost exactly in line with its 20-day average of 4.58, with a z-score of just 0.25. The 52-week range on the PCR runs from 0.04 to 4.90, so the current reading is near the high end of recent history but has been elevated for weeks. This is a structurally put-heavy name rather than one experiencing a sudden defensive surge. Options traders have not materially changed their lean heading into the November 11 print.

Valuation factors tell a mixed story. The EV/EBITDA multiple has compressed 30 days running, down 0.11 turns over the period, while the price-to-book ratio has fallen 0.17 over the same window. At the same time, the earnings yield ranks in the 88th percentile and the EV/EBIT factor scores in the 92nd, meaning the stock is cheap on earnings-based measures relative to the broader universe. The 90-day forward EPS momentum factor ranks in the 83rd percentile, though 30-day momentum is more subdued at the 44th. The bulls' case rests on exactly this: a business with near-100% managed services renewal rates, cloud revenue above 30% of sales, and a large addressable market still in early innings of cloud migration, all trading at a low multiple. The short score of 55 is middling, having been roughly stable for the past two weeks after a gradual drift higher through the second half of the year.

Among institutional holders, Pzena Investment Management has built a 13.2% stake as of its July 2026 13G/A filing, up from 11.3% previously, making it the largest disclosed 5%-plus holder. FMR has moved in the opposite direction, trimming from 11.2% to 9.4% as of August. No 13D activist holders are on the register. As always, these figures are event-driven disclosures around the 5% threshold and may not reflect current positions precisely. Janus Henderson has already fallen below 5%, disclosing a 2.3% stake in its most recent amendment, down from 5.2%.

Peers had a rough Tuesday. CTSH fell 1.9% on the day and ACN dropped 2.4%, while IT (Gartner) posted an unusually sharp 13.2% single-day decline. KD (Kyndryl) is down 8.6% on the week. DOX's 1.1% gain on the week sits in a relatively better position than most of its correlated peers, though the group's broad weakness adds context to the analyst pressure.

Wikipedia attention for Amdocs has spiked, with retail interest running 2.3 standard deviations above its 90-day average as of October 19, the highest attention reading the alt data shows. Whether that reflects earnings preview interest or reaction to recent analyst noise, it represents a level of retail focus the stock rarely attracts. The November 11 print will be watched most closely on two fronts: whether AT&T and T-Mobile customer revenue trends have stabilised, and whether management's Q4 guidance gives the remaining bulls reason to hold through what has been a year of steadily declining targets from every major firm covering the name.